Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling

Frédéric Ooms, Johan Wouters, Olivier Oscari, Thierry Happaerts, Géraldine Bouchard, Pierre Alain Carrupt, Bernard Testa, Didier M. Lambert

Research output: Contribution to journalArticle

Abstract

A set of 29 3-alkyl 5-arylimidazolidinediones (hydantoins) with affinity for the human cannabinoid CB1 receptor was studied for their lipophilicity and conformational properties in order to delineate a pharmacophore. These molecules constitute a new template for cannabinoid receptor recognition, since (a) their structure differs from that of classical cannabinoid ligands and (b) antagonism is the mechanism of action of at least three compounds (20, 21, and 23). Indeed, in the [35S]-GTPγS binding assay using rat cerebellum homogenates, they behave as antagonists without any inverse agonism component. Using a set of selected compounds, experimental lipophilicity was measured by RP-HPLC and calculated by a fragmental method (CLOGP) and a conformation-dependent method (CLIP based on the molecular lipophilicity potential). These approaches revealed two models which differentiate the binding mode of nonpolar and polar hydantoins and which could explain, at least for compounds 20, 21, and 23, the mechanism of action of this new family of cannabinoid ligands.

Original languageEnglish
Pages (from-to)1748-1756
Number of pages9
JournalJournal of Medicinal Chemistry
Volume45
Issue number9
DOIs
Publication statusPublished - 25 Apr 2002

Fingerprint

Hydantoins
Cannabinoid Receptor CB1
Molecular modeling
Cannabinoids
Ligands
Cannabinoid Receptors
Cerebellum
Conformations
Rats
Assays
High Pressure Liquid Chromatography
Molecules
compound 20

Cite this

Ooms, Frédéric ; Wouters, Johan ; Oscari, Olivier ; Happaerts, Thierry ; Bouchard, Géraldine ; Carrupt, Pierre Alain ; Testa, Bernard ; Lambert, Didier M. / Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists : Synthesis, lipophilicity, affinity, and molecular modeling. In: Journal of Medicinal Chemistry. 2002 ; Vol. 45, No. 9. pp. 1748-1756.
@article{7ee2d11ee243426fb83509d7f3cc0f1d,
title = "Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling",
abstract = "A set of 29 3-alkyl 5-arylimidazolidinediones (hydantoins) with affinity for the human cannabinoid CB1 receptor was studied for their lipophilicity and conformational properties in order to delineate a pharmacophore. These molecules constitute a new template for cannabinoid receptor recognition, since (a) their structure differs from that of classical cannabinoid ligands and (b) antagonism is the mechanism of action of at least three compounds (20, 21, and 23). Indeed, in the [35S]-GTPγS binding assay using rat cerebellum homogenates, they behave as antagonists without any inverse agonism component. Using a set of selected compounds, experimental lipophilicity was measured by RP-HPLC and calculated by a fragmental method (CLOGP) and a conformation-dependent method (CLIP based on the molecular lipophilicity potential). These approaches revealed two models which differentiate the binding mode of nonpolar and polar hydantoins and which could explain, at least for compounds 20, 21, and 23, the mechanism of action of this new family of cannabinoid ligands.",
author = "Fr{\'e}d{\'e}ric Ooms and Johan Wouters and Olivier Oscari and Thierry Happaerts and G{\'e}raldine Bouchard and Carrupt, {Pierre Alain} and Bernard Testa and Lambert, {Didier M.}",
year = "2002",
month = "4",
day = "25",
doi = "10.1021/jm010896y",
language = "English",
volume = "45",
pages = "1748--1756",
journal = "J. Med. Chem.",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "9",

}

Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists : Synthesis, lipophilicity, affinity, and molecular modeling. / Ooms, Frédéric; Wouters, Johan; Oscari, Olivier; Happaerts, Thierry; Bouchard, Géraldine; Carrupt, Pierre Alain; Testa, Bernard; Lambert, Didier M.

In: Journal of Medicinal Chemistry, Vol. 45, No. 9, 25.04.2002, p. 1748-1756.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB1 cannabinoid receptor ligands and potential antagonists

T2 - Synthesis, lipophilicity, affinity, and molecular modeling

AU - Ooms, Frédéric

AU - Wouters, Johan

AU - Oscari, Olivier

AU - Happaerts, Thierry

AU - Bouchard, Géraldine

AU - Carrupt, Pierre Alain

AU - Testa, Bernard

AU - Lambert, Didier M.

PY - 2002/4/25

Y1 - 2002/4/25

N2 - A set of 29 3-alkyl 5-arylimidazolidinediones (hydantoins) with affinity for the human cannabinoid CB1 receptor was studied for their lipophilicity and conformational properties in order to delineate a pharmacophore. These molecules constitute a new template for cannabinoid receptor recognition, since (a) their structure differs from that of classical cannabinoid ligands and (b) antagonism is the mechanism of action of at least three compounds (20, 21, and 23). Indeed, in the [35S]-GTPγS binding assay using rat cerebellum homogenates, they behave as antagonists without any inverse agonism component. Using a set of selected compounds, experimental lipophilicity was measured by RP-HPLC and calculated by a fragmental method (CLOGP) and a conformation-dependent method (CLIP based on the molecular lipophilicity potential). These approaches revealed two models which differentiate the binding mode of nonpolar and polar hydantoins and which could explain, at least for compounds 20, 21, and 23, the mechanism of action of this new family of cannabinoid ligands.

AB - A set of 29 3-alkyl 5-arylimidazolidinediones (hydantoins) with affinity for the human cannabinoid CB1 receptor was studied for their lipophilicity and conformational properties in order to delineate a pharmacophore. These molecules constitute a new template for cannabinoid receptor recognition, since (a) their structure differs from that of classical cannabinoid ligands and (b) antagonism is the mechanism of action of at least three compounds (20, 21, and 23). Indeed, in the [35S]-GTPγS binding assay using rat cerebellum homogenates, they behave as antagonists without any inverse agonism component. Using a set of selected compounds, experimental lipophilicity was measured by RP-HPLC and calculated by a fragmental method (CLOGP) and a conformation-dependent method (CLIP based on the molecular lipophilicity potential). These approaches revealed two models which differentiate the binding mode of nonpolar and polar hydantoins and which could explain, at least for compounds 20, 21, and 23, the mechanism of action of this new family of cannabinoid ligands.

UR - http://www.scopus.com/inward/record.url?scp=0037171832&partnerID=8YFLogxK

U2 - 10.1021/jm010896y

DO - 10.1021/jm010896y

M3 - Article

VL - 45

SP - 1748

EP - 1756

JO - J. Med. Chem.

JF - J. Med. Chem.

SN - 0022-2623

IS - 9

ER -